234 related articles for article (PubMed ID: 30476237)
1. Integrative cross-platform analyses identify enhanced heterotrophy as a metabolic hallmark in glioblastoma.
Prabhu AH; Kant S; Kesarwani P; Ahmed K; Forsyth P; Nakano I; Chinnaiyan P
Neuro Oncol; 2019 Feb; 21(3):337-347. PubMed ID: 30476237
[TBL] [Abstract][Full Text] [Related]
2. Molecular characterization of long-term survivors of glioblastoma using genome- and transcriptome-wide profiling.
Reifenberger G; Weber RG; Riehmer V; Kaulich K; Willscher E; Wirth H; Gietzelt J; Hentschel B; Westphal M; Simon M; Schackert G; Schramm J; Matschke J; Sabel MC; Gramatzki D; Felsberg J; Hartmann C; Steinbach JP; Schlegel U; Wick W; Radlwimmer B; Pietsch T; Tonn JC; von Deimling A; Binder H; Weller M; Loeffler M;
Int J Cancer; 2014 Oct; 135(8):1822-31. PubMed ID: 24615357
[TBL] [Abstract][Full Text] [Related]
3. Platform-Independent Genome-Wide Pattern of DNA Copy-Number Alterations Predicting Astrocytoma Survival and Response to Treatment Revealed by the GSVD Formulated as a Comparative Spectral Decomposition.
Aiello KA; Alter O
PLoS One; 2016; 11(10):e0164546. PubMed ID: 27798635
[TBL] [Abstract][Full Text] [Related]
4. Human TERT promoter mutation enables survival advantage from MGMT promoter methylation in IDH1 wild-type primary glioblastoma treated by standard chemoradiotherapy.
Nguyen HN; Lie A; Li T; Chowdhury R; Liu F; Ozer B; Wei B; Green RM; Ellingson BM; Wang HJ; Elashoff R; Liau LM; Yong WH; Nghiemphu PL; Cloughesy T; Lai A
Neuro Oncol; 2017 Mar; 19(3):394-404. PubMed ID: 27571882
[TBL] [Abstract][Full Text] [Related]
5. Metabolic remodeling contributes towards an immune-suppressive phenotype in glioblastoma.
Kesarwani P; Prabhu A; Kant S; Chinnaiyan P
Cancer Immunol Immunother; 2019 Jul; 68(7):1107-1120. PubMed ID: 31119318
[TBL] [Abstract][Full Text] [Related]
6. Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network.
Weller M; Felsberg J; Hartmann C; Berger H; Steinbach JP; Schramm J; Westphal M; Schackert G; Simon M; Tonn JC; Heese O; Krex D; Nikkhah G; Pietsch T; Wiestler O; Reifenberger G; von Deimling A; Loeffler M
J Clin Oncol; 2009 Dec; 27(34):5743-50. PubMed ID: 19805672
[TBL] [Abstract][Full Text] [Related]
7. Loss of 5-hydroxymethylcytosine and intratumoral heterogeneity as an epigenomic hallmark of glioblastoma.
Kraus TF; Kolck G; Greiner A; Schierl K; Guibourt V; Kretzschmar HA
Tumour Biol; 2015 Nov; 36(11):8439-46. PubMed ID: 26022161
[TBL] [Abstract][Full Text] [Related]
8. Loss of ATRX, associated with DNA methylation pattern of chromosome end, impacted biological behaviors of astrocytic tumors.
Cai J; Chen J; Zhang W; Yang P; Zhang C; Li M; Yao K; Wang H; Li Q; Jiang C; Jiang T
Oncotarget; 2015 Jul; 6(20):18105-15. PubMed ID: 25971279
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of MGMT promoter methylation and TP53 mutation in glioblastomas depends on IDH1 mutation.
Wang K; Wang YY; Ma J; Wang JF; Li SW; Jiang T; Dai JP
Asian Pac J Cancer Prev; 2014; 15(24):10893-8. PubMed ID: 25605197
[TBL] [Abstract][Full Text] [Related]
10. Intratumoral heterogeneity identified at the epigenetic, genetic and transcriptional level in glioblastoma.
Parker NR; Hudson AL; Khong P; Parkinson JF; Dwight T; Ikin RJ; Zhu Y; Cheng ZJ; Vafaee F; Chen J; Wheeler HR; Howell VM
Sci Rep; 2016 Mar; 6():22477. PubMed ID: 26940435
[TBL] [Abstract][Full Text] [Related]
11. Metabolomic Profiles of Human Glioma Inform Patient Survival.
Scott AJ; Correa LO; Edwards DM; Sun Y; Ravikumar V; Andren AC; Zhang L; Srinivasan S; Jairath N; Verbal K; Muraszko K; Sagher O; Carty SA; Hervey-Jumper S; Orringer D; Kim MM; Junck L; Umemura Y; Leung D; Venneti S; Camelo-Piragua S; Lawrence TS; Ippolito JE; Al-Holou WN; Chinnaiyan P; Heth J; Rao A; Lyssiotis CA; Wahl DR
Antioxid Redox Signal; 2023 Nov; 39(13-15):942-956. PubMed ID: 36852494
[No Abstract] [Full Text] [Related]
12. Gliomatosis cerebri: no evidence for a separate brain tumor entity.
Herrlinger U; Jones DTW; Glas M; Hattingen E; Gramatzki D; Stuplich M; Felsberg J; Bähr O; Gielen GH; Simon M; Wiewrodt D; Schabet M; Hovestadt V; Capper D; Steinbach JP; von Deimling A; Lichter P; Pfister SM; Weller M; Reifenberger G
Acta Neuropathol; 2016 Feb; 131(2):309-319. PubMed ID: 26493382
[TBL] [Abstract][Full Text] [Related]
13. Expression of glioma stem cell marker CD133 and O6-methylguanine-DNA methyltransferase is associated with resistance to radiotherapy in gliomas.
He J; Shan Z; Li L; Liu F; Liu Z; Song M; Zhu H
Oncol Rep; 2011 Nov; 26(5):1305-13. PubMed ID: 21769436
[TBL] [Abstract][Full Text] [Related]
14. Intratumoral homogeneity of MGMT promoter hypermethylation as demonstrated in serial stereotactic specimens from anaplastic astrocytomas and glioblastomas.
Grasbon-Frodl EM; Kreth FW; Ruiter M; Schnell O; Bise K; Felsberg J; Reifenberger G; Tonn JC; Kretzschmar HA
Int J Cancer; 2007 Dec; 121(11):2458-64. PubMed ID: 17691113
[TBL] [Abstract][Full Text] [Related]
15. Progressive adult primary glioblastoma in the medulla oblongata with an unmethylated MGMT promoter and without an IDH mutation.
Yoshikawa A; Nakada M; Watanabe T; Hayashi Y; Sabit H; Kato Y; Suzuki S; Ooi A; Sato H; Hamada J
Brain Tumor Pathol; 2013 Jul; 30(3):175-9. PubMed ID: 23053494
[TBL] [Abstract][Full Text] [Related]
16. WT1 expression increases with malignancy and indicates unfavourable outcome in astrocytoma.
Rauscher J; Beschorner R; Gierke M; Bisdas S; Braun C; Ebner FH; Schittenhelm J
J Clin Pathol; 2014 Jul; 67(7):556-61. PubMed ID: 24607494
[TBL] [Abstract][Full Text] [Related]
17. The metabolomic signature of malignant glioma reflects accelerated anabolic metabolism.
Chinnaiyan P; Kensicki E; Bloom G; Prabhu A; Sarcar B; Kahali S; Eschrich S; Qu X; Forsyth P; Gillies R
Cancer Res; 2012 Nov; 72(22):5878-88. PubMed ID: 23026133
[TBL] [Abstract][Full Text] [Related]
18. Differential gene methylation in paired glioblastomas suggests a role of immune response pathways in tumor progression.
Alentorn A; Durán-Peña A; Malousi A; Marie Y; Mokhtari K; Sanson M; Hoang-Xuan K; Delattre JY; Idbaih A; Vecht C
J Neurooncol; 2015 Sep; 124(3):385-92. PubMed ID: 26224161
[TBL] [Abstract][Full Text] [Related]
19. Temporal stability of MGMT promoter methylation in glioblastoma patients undergoing STUPP protocol.
O'Regan CJ; Kearney H; Beausang A; Farrell MA; Brett FM; Cryan JB; Loftus TE; Buckley PG
J Neurooncol; 2018 Apr; 137(2):233-240. PubMed ID: 29264834
[TBL] [Abstract][Full Text] [Related]
20. Pathology: commonly monitored glioblastoma markers: EFGR, EGFRvIII, PTEN, and MGMT.
Camara-Quintana JQ; Nitta RT; Li G
Neurosurg Clin N Am; 2012 Apr; 23(2):237-46, viii. PubMed ID: 22440867
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
